Document is current
Any future updates will be listed below
-
Authors
Oh, Hamilton Se-Hwee https://orcid.org/0000-0001-8192-7593
Urey, Deniz Yagmur
Karlsson, Linda https://orcid.org/0000-0002-0630-772X
Zhu, Zeyu
Shen, Yuanyuan
Farinas, Amelia
Timsina, Jigyasha
Duggan, Michael R. https://orcid.org/0000-0002-1029-4423
Chen, Jingsha
Guldner, Ian H.
Morshed, Nader https://orcid.org/0000-0002-0346-9651
Yang, Chengran https://orcid.org/0000-0003-4577-5590
Western, Daniel https://orcid.org/0000-0003-3725-9553
Ali, Muhammad https://orcid.org/0000-0002-1399-6631
Le Guen, Yann https://orcid.org/0000-0001-6649-8364
Trelle, Alexandra
Herukka, Sanna-Kaisa
Rauramaa, Tuomas
Hiltunen, Mikko
Lipponen, Anssi https://orcid.org/0000-0002-4403-9084
Luikku, Antti J.
Poston, Kathleen L. https://orcid.org/0000-0003-3424-7143
Mormino, Elizabeth
Wagner, Anthony D. https://orcid.org/0000-0003-0624-4543
Wilson, Edward N. https://orcid.org/0000-0003-0640-5247
Channappa, Divya
Leinonen, Ville
Stevens, Beth
Ehrenberg, Alexander J.
Gottesman, Rebecca F. https://orcid.org/0000-0002-9504-1256
Coresh, Josef https://orcid.org/0000-0002-4598-0669
Walker, Keenan A. https://orcid.org/0000-0002-5989-9853
Zetterberg, Henrik https://orcid.org/0000-0003-3930-4354
Bennett, David A.
Franzmeier, Nicolai https://orcid.org/0000-0001-9736-2283
Hansson, Oskar https://orcid.org/0000-0001-8467-7286
Cruchaga, Carlos https://orcid.org/0000-0002-0276-2899
Wyss-Coray, Tony https://orcid.org/0000-0001-5893-0831
- License Information
-
More Information
Article History
Received: 5 July 2024
Accepted: 4 February 2025
First Online: 31 March 2025
Competing interests
: T.W-C. and H.S.-H.O. are cofounders and scientific advisers of Teal Omics and have received equity stakes. C.C. has received research support from GSK and Eisai. C.C. is a member of the scientific advisory board of Circular Genomics and owns stocks. C.C. is a member of the scientific advisory board of ADmit. C.C. and M.A. have an invention disclosure for AT1 prediction models, including protein IDs, weights, cutoffs and algorithms. O.H. has acquired research support (for the institution) from AVID Radiopharmaceuticals, Biogen, C2N Diagnostics, Eli Lilly, Eisai, Fujirebio, GE Healthcare and Roche. In the past 2 years, he has received consultancy and speaker fees from ALZpath, BioArctic, Biogen, Bristol Myers Squibb, Eisai, Eli Lilly, Fujirebio, Merck, Novartis, Novo Nordisk, Roche, Sanofi and Siemens. H.Z. has served at scientific advisory boards or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZPath, Amylyx, Annexon, Apellis, Artery Therapeutics, AZTherapies, Cognito Therapeutics, Cognition Therapeutics, Denali, Eisai, Labcorp, Merry Life Biomedical, NervGen Pharma, Novo Nordisk, OptoCeutics, Passage Bio, Pinteon Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics and Wave, has given lectures in symposia sponsored by AlzeCure, Biogen, Cellectricon, Fujirebio, Lilly, Novo Nordisk and Roche, and is a cofounder of Brain Biomarker Solutions in Gothenburg, which is a part of the GU Ventures Incubator Program (outside the submitted work). The other authors declare no competing interests.
